e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Cellular and molecular aspects of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Exhaled condensate of endothelin-1 and exhaled nitric oxide are increased in COPD patients with secondary pulmonary hypertension
P. Carratu, C. Scoditti, G. E. Carpagnano, M. Maniscalco, M. T. Seccia, G. Di Gioia, P. Pierucci, A. Spanevello, M. P. Foschino, O. Resta (Bari, Foggia, Naples, Italy)
Source:
Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Session:
Cellular and molecular aspects of pulmonary hypertension
Session type:
Electronic Poster Discussion
Number:
492
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Carratu, C. Scoditti, G. E. Carpagnano, M. Maniscalco, M. T. Seccia, G. Di Gioia, P. Pierucci, A. Spanevello, M. P. Foschino, O. Resta (Bari, Foggia, Naples, Italy). Exhaled condensate of endothelin-1 and exhaled nitric oxide are increased in COPD patients with secondary pulmonary hypertension. Eur Respir J 2007; 30: Suppl. 51, 492
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Exhaled breath condensate pH and exhaled nitric oxide in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: Suppl. 45, 18s
Year: 2003
Investigation of nitric oxide level in the exhaled breath condensate in asthma and COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 281s
Year: 2005
Elevated exhaled nitric oxide without acidification of exhaled breath condensate in patients with mild asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 506s
Year: 2002
Nitrite/nitrate levels in exhaled breath condensate are increased but exhaled nitric oxide levels were not in COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 788s
Year: 2006
Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma
Source: Annual Congress 2008 - Inflammatory biomarkers
Year: 2008
Exhaled nitric oxide and COPD
Source: Eur Respir J 2010; 36: 692
Year: 2010
Fractionated exhaled nitric oxide in COPD patients
Source: International Congress 2019 – Advances in clinical management of COPD
Year: 2019
Nasal nitric oxide, exhaled nitric oxide and exhaled breath condensate pH measurements in children with allergic disease
Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement
Year: 2008
Concentration of nitric oxide in exhaled air (eNO) in patients with sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 434s
Year: 2002
Exhaled nitric oxide and pulmonary function tests in children with asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 759s
Year: 2007
Exhaled nitric oxide in patients with idiopathic pulmonary fibrosis and pulmonary hypertension
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
Exhaled nitric oxide levels in patients with pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Diagnosing asthma using exhaled nitric oxide (eNO) measurements
Source: Annual Congress 2003 - Recognition, management and assessment of asthma including severe asthma
Year: 2003
Comparisons for concentration in exhaled nitric oxide between patients with bronchial asthma and COPD
Source: Annual Congress 2007 - Pathophysiology and assessment of COPD
Year: 2007
Exhaled nitric oxide predicts response to treatment in COPD patients with exacerbation
Source: Annual Congress 2008 - Phenotyping of asthma and COPD
Year: 2008
Exhaled nitric oxide and exhaled breath condensate pH in smoking asthma
Source: Annual Congress 2009 - Airway inflammation and asthma control
Year: 2009
Fractional exhaled nitric oxide in pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
Exhaled nitric oxide (NO) in patients with chronic cough
Source: Eur Respir J 2004; 24: Suppl. 48, 580s
Year: 2004
Predicting response to corticosteroid in COPD using exhaled nitric oxide
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Exhaled nitric oxide in mustard airway disease
Source: International Congress 2018 – Occupational and environmental lung diseases: influence on the airway and interstitium
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept